Study Overview: This study is testing a new medicine called VNX001 to see if it helps reduce bladder pain in people with a condition called interstitial cystitis/bladder pain syndrome (IC/BPS). VNX001 combines two existing medicines, lidocaine (a numbing medicine) and heparin (a blood thinner). The study will compare VNX001 to its parts and a placebo, which is a substance that looks like medicine but doesn't do anything. A total of 120 to 180 people from around the United States will participate.
Eligibility: To join, you must be 18 or older, have had IC/BPS for at least nine months, and have moderate to severe bladder pain. You cannot join if you are pregnant, have allergies to lidocaine or heparin, take certain medications, or have other medical conditions that might interfere with the study.
- The study involves a single dose and possibly a follow-up dose of VNX001.
- Participants might receive a placebo, VNX001, or its parts randomly.
- There are certain health conditions and medications that can prevent participation.
If interested, discuss with your doctor to see if this study is right for you.